BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.7%

Neg 0% Neu 88.7% Pos 0%

BTIG analyst Jeet Mukherjee reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $55 price target.

Comments

No comments yet. Be the first!